The Globe and Mass HIgh Tech report that, Anlylam, a Cambridge company working on drugs targets based on RNAi, is ending its alliance with Novartis and laying off up to 30 percent of its employees. Click here for the company’s press release.
The company has been working closely with the Koch Institute at MIT..